MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.ÿ
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/20/12 | $5,250,000 | Series B |
RTP Ventures | undisclosed |
